PubMed

Interaction of Leptin and Amylin in the Long-term Maintenance of Weight Loss in Diet-induced Obese Rats.

Trevaskis JL, Lei C, Koda JE, Weyer C, Parkes DG, Roth JD.

Obesity (Silver Spring). 2009 Jun 18. [Epub ahead of print]PMID: 19543217 [PubMed - as supplied by publisher]Related articles

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, Koda JE, Weyer C.

Obesity (Silver Spring). 2009 Sep;17(9):1736-43. Epub 2009 Jun 11.PMID: 19521351 [PubMed - indexed for MEDLINE]Related articles

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.

Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C.

Diabetes Care. 2008 Sep;31(9):1816-23. Epub 2008 Jun 20.PMID: 18753666 [PubMed - indexed for MEDLINE]Related articlesFree article

Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms.

Trevaskis JL, Coffey T, Cole R, Lei C, Wittmer C, Walsh B, Weyer C, Koda J, Baron AD, Parkes DG, Roth JD.

Endocrinology. 2008 Nov;149(11):5679-87. Epub 2008 Jul 31.PMID: 18669592 [PubMed - indexed for MEDLINE]Related articlesFree article

Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.

Roth JD, Trevaskis JL, Wilson J, Lei C, Athanacio J, Mack C, Kesty NC, Coffey T, Weyer C, Parkes DG.

Int J Obes (Lond). 2008 Aug;32(8):1201-10. Epub 2008 Jun 17.PMID: 18560368 [PubMed - indexed for MEDLINE]Related articles

Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy.

Chen HC, Roth JD, Schroeder BE, Weyer C.

Curr Diabetes Rev. 2008 May;4(2):79-91. Review.PMID: 18473755 [PubMed - indexed for MEDLINE]Related articles

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies.

Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD.

Proc Natl Acad Sci U S A. 2008 May 20;105(20):7257-62. Epub 2008 May 5.PMID: 18458326 [PubMed - indexed for MEDLINE]Related articlesFree article

Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals.

Koska J, Stefan N, Permana PA, Weyer C, Sonoda M, Bogardus C, Smith SR, Joanisse DR, Funahashi T, Krakoff J, Bunt JC.

Am J Clin Nutr. 2008 Feb;87(2):295-302.PMID: 18258617 [PubMed - indexed for MEDLINE]Related articlesFree article

Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity.

Roth JD, Coffey T, Jodka CM, Maier H, Athanacio JR, Mack CM, Weyer C, Parkes DG.

Endocrinology. 2007 Dec;148(12):6054-61. Epub 2007 Aug 30.PMID: 17761760 [PubMed - indexed for MEDLINE]Related articlesFree article

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.

Smith SR, Blundell JE, Burns C, Ellero C, Schroeder BE, Kesty NC, Chen KS, Halseth AE, Lush CW, Weyer C.

Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E620-7. Epub 2007 May 15.PMID: 17505051 [PubMed - indexed for MEDLINE]Related articlesFree article

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C.

J Clin Endocrinol Metab. 2007 Aug;92(8):2977-83. Epub 2007 May 15.PMID: 17504894 [PubMed - indexed for MEDLINE]Related articlesFree article

Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.

Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Lush CW, Chen K, Lacerte C, Burns C, McKay R, Weyer C, Horowitz M.

Obesity (Silver Spring). 2007 May;15(5):1179-86.PMID: 17495194 [PubMed - indexed for MEDLINE]Related articles

Food, mood and mental health.

Ryrie I, Cornah D, Van de Weyer C.

Ment Health Today. 2006 Feb:23-6. No abstract available. PMID: 16491737 [PubMed - indexed for MEDLINE]Related articles

The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.

Amiel SA, Heller SR, Macdonald IA, Schwartz SL, Klaff LJ, Ruggles JA, Weyer C, Kolterman OG, Maggs DG.

Diabetes Obes Metab. 2005 Sep;7(5):504-16.PMID: 16050943 [PubMed - indexed for MEDLINE]Related articles

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.

Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, Maggs DG, Kolterman OG, Weyer C.

Exp Clin Endocrinol Diabetes. 2005 Apr;113(4):199-204.PMID: 15891954 [PubMed - indexed for MEDLINE]Related articles

Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.

Purnell JQ, Weyer C.

Treat Endocrinol. 2003;2(1):33-47. Review.PMID: 15871553 [PubMed - indexed for MEDLINE]Related articles

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.

Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Strobel S, Wang Y, Burns C, Lush C, Weyer C, Horowitz M.

Diabetologia. 2005 May;48(5):838-48. Epub 2005 Apr 21.PMID: 15843914 [PubMed - indexed for MEDLINE]Related articles

Properties of pramlintide and insulin upon mixing.

Weyer C, Fineman MS, Strobel S, Shen L, Data J, Kolterman OG, Sylvestri MF.

Am J Health Syst Pharm. 2005 Apr 15;62(8):816-22.PMID: 15821274 [PubMed - indexed for MEDLINE]Related articles

Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.

Ceriello A, Piconi L, Quagliaro L, Wang Y, Schnabel CA, Ruggles JA, Gloster MA, Maggs DG, Weyer C.

Diabetes Care. 2005 Mar;28(3):632-7.PMID: 15735200 [PubMed - indexed for MEDLINE]Related articlesFree article

Pancreatic polypeptide is involved in the regulation of body weight in pima Indian male subjects.

Koska J, DelParigi A, de Courten B, Weyer C, Tataranni PA.

Diabetes. 2004 Dec;53(12):3091-6.PMID: 15561938 [PubMed - indexed for MEDLINE]Related articlesFree article

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG.

Diabet Med. 2004 Nov;21(11):1204-12.PMID: 15498087 [PubMed - indexed for MEDLINE]Related articles

Exaggerated insulin secretion in Pima Indians and African-Americans but higher insulin resistance in Pima Indians compared to African-Americans and Caucasians.

Stefan N, Stumvoll M, Weyer C, Bogardus C, Tataranni PA, Pratley RE.

Diabet Med. 2004 Oct;21(10):1090-5.PMID: 15384955 [PubMed - indexed for MEDLINE]Related articles

Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects.

Heise T, Heinemann L, Heller S, Weyer C, Wang Y, Strobel S, Kolterman O, Maggs D.

Metabolism. 2004 Sep;53(9):1227-32.PMID: 15334389 [PubMed - indexed for MEDLINE]Related articles

Endogenous glucose production, insulin sensitivity, and insulin secretion in normal glucose-tolerant Pima Indians with low birth weight.

Stefan N, Weyer C, Levy-Marchal C, Stumvoll M, Knowler WC, Tataranni PA, Bogardus C, Pratley RE.

Metabolism. 2004 Jul;53(7):904-11.PMID: 15254885 [PubMed - indexed for MEDLINE]Related articles

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.

Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C.

Obes Res. 2004 Apr;12(4):661-8.PMID: 15090634 [PubMed - indexed for MEDLINE]Related articles

Parasympathetic blockade attenuates augmented pancreatic polypeptide but not insulin secretion in Pima Indians.

Vozarova de Courten B, Weyer C, Stefan N, Horton M, DelParigi A, Havel P, Bogardus C, Tataranni PA.

Diabetes. 2004 Mar;53(3):663-71.PMID: 14988250 [PubMed - indexed for MEDLINE]Related articlesFree article

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C.

Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):55-60.PMID: 14737746 [PubMed - indexed for MEDLINE]Related articles

Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.

Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C.

Metabolism. 2003 Dec;52(12):1638-42.PMID: 14669170 [PubMed - indexed for MEDLINE]Related articles

Plasma adiponectin and endogenous glucose production in humans.

Stefan N, Stumvoll M, Vozarova B, Weyer C, Funahashi T, Matsuzawa Y, Bogardus C, Tataranni PA.

Diabetes Care. 2003 Dec;26(12):3315-9.PMID: 14633820 [PubMed - indexed for MEDLINE]Related articlesFree article

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.

Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D, Kolterman O, Weyer C.

Diabetes Obes Metab. 2003 Nov;5(6):408-14.PMID: 14617226 [PubMed - indexed for MEDLINE]Related articles

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

Diabetes Care. 2003 Nov;26(11):3074-9.PMID: 14578242 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of cortisol on muscle sympathetic nerve activity in Pima Indians and Caucasians.

Vozarova B, Weyer C, Snitker S, Gautier JF, Cizza G, Chrousos G, Ravussin E, Tataranni PA.

J Clin Endocrinol Metab. 2003 Jul;88(7):3218-26.PMID: 12843168 [PubMed - indexed for MEDLINE]Related articlesFree article

Relation between physical activity and obesity.

Salbe AD, Weyer C, Harper I, Lindsay RS, Ravussin E, Tataranni PA.

Am J Clin Nutr. 2003 Jul;78(1):193-4; author reply 194-5. No abstract available. PMID: 12816794 [PubMed - indexed for MEDLINE]Related articlesFree article

Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion.

Pratley RE, Weyer C.

Curr Diab Rep. 2002 Jun;2(3):242-8. Review.PMID: 12643180 [PubMed - indexed for MEDLINE]Related articles

Laminin alpha-1, alpha-3, and alpha-5 chain expression in human prepubertal [correction of prepubetal] benign prostate glands and adult benign and malignant prostate glands.

Brar PK, Dalkin BL, Weyer C, Sallam K, Virtanen I, Nagle RB.

Prostate. 2003 Apr 1;55(1):65-70.PMID: 12640662 [PubMed - indexed for MEDLINE]Related articles

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG.

Diabetes Care. 2003 Mar;26(3):784-90.PMID: 12610038 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR.

Diabetes Care. 2003 Jan;26(1):1-8.PMID: 12502651 [PubMed - indexed for MEDLINE]Related articlesFree article

Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.

Baron AD, Kim D, Weyer C.

Curr Drug Targets Immune Endocr Metabol Disord. 2002 Apr;2(1):63-82. Review.PMID: 12477297 [PubMed - indexed for MEDLINE]Related articles

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.

Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG.

Horm Metab Res. 2002 Sep;34(9):504-8.PMID: 12384827 [PubMed - indexed for MEDLINE]Related articles

Plasma adiponectin levels are not associated with fat oxidation in humans.

Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Ravussin E, Weyer C, Tataranni PA.

Obes Res. 2002 Oct;10(10):1016-20.PMID: 12376582 [PubMed - indexed for MEDLINE]Related articles

Low plasma adiponectin concentrations do not predict weight gain in humans.

Vozarova B, Stefan N, Lindsay RS, Krakoff J, Knowler WC, Funahashi T, Matsuzawa Y, Stumvoll M, Weyer C, Tataranni PA.

Diabetes. 2002 Oct;51(10):2964-7.PMID: 12351434 [PubMed - indexed for MEDLINE]Related articlesFree article

Assessing risk factors for obesity between childhood and adolescence: II. Energy metabolism and physical activity.

Salbe AD, Weyer C, Harper I, Lindsay RS, Ravussin E, Tataranni PA.

Pediatrics. 2002 Aug;110(2 Pt 1):307-14.PMID: 12165583 [PubMed - indexed for MEDLINE]Related articlesFree article

Assessing risk factors for obesity between childhood and adolescence: I. Birth weight, childhood adiposity, parental obesity, insulin, and leptin.

Salbe AD, Weyer C, Lindsay RS, Ravussin E, Tataranni PA.

Pediatrics. 2002 Aug;110(2 Pt 1):299-306.PMID: 12165582 [PubMed - indexed for MEDLINE]Related articlesFree article

Differences in oral temperature and body shape in two populations with different propensities for obesity.

Vozarova B, Weyer C, Bogardus C, Ravussin E, Tataranni PA.

Ann N Y Acad Sci. 2002 Jun;967:516-21.PMID: 12079882 [PubMed - indexed for MEDLINE]Related articles

Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.

Edelman SV, Weyer C.

Diabetes Technol Ther. 2002;4(2):175-89. Review.PMID: 12079621 [PubMed - indexed for MEDLINE]Related articles

Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans.

Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA.

Diabetes. 2002 Jun;51(6):1884-8.PMID: 12031977 [PubMed - indexed for MEDLINE]Related articlesFree article

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.

Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG.

Diabetes Technol Ther. 2002;4(1):51-61.PMID: 12017421 [PubMed - indexed for MEDLINE]Related articles

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.

Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG.

Metabolism. 2002 May;51(5):636-41.PMID: 11979398 [PubMed - indexed for MEDLINE]Related articles

[Results of a structured hypertension teaching and treatment programme]

Heise T, Jennen E, Hochlenert D, Weyer C, Sawicki PT.

Z Gastroenterol. 2002 Apr;40 Suppl 1:S27-S32. German. PMID: 11930287 [PubMed - indexed for MEDLINE]Related articles

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG.

Diabetes Care. 2002 Apr;25(4):724-30.PMID: 11919132 [PubMed - indexed for MEDLINE]Related articlesFree article